KDM5D Knockout PaTu 8988t Polyclonal Cells are a CRISPR/Cas9-edited polyclonal population for loss-of-function studies of KDM5D. Derived from the PaTu 8988t pancreatic ductal adenocarcinoma line, this heterogeneous cell pool carries targeted disruption of the KDM5D gene via CRISPR/Cas9 genome editing. It provides a genetically modified model for investigating KDM5D-dependent mechanisms in metastatic cancer, with a mixed genotypic background that reflects population-level gene perturbation, making it suitable for pooled screening and functional genomics applications.
The parental PaTu 8988t cell line, established from a liver metastasis of a human pancreatic ductal adenocarcinoma, is a well-characterized model for metastatic pancreatic cancer. Its tumorigenic properties and hepatic origin render it a robust system for both in vitro and in vivo metastasis studies. In pancreatic oncology, PaTu 8988t cells are used to evaluate gene functions in advanced disease and to screen therapeutic vulnerabilities.
KDM5D encodes a histone H3K4 demethylase that removes di- and trimethyl marks from H3K4 (H3K4me2/me3), converting active chromatin to a repressed state. It acts as a transcriptional repressor within SIN3A-HDAC co-repressor complexes and is recruited by AR and REST to specific genomic loci. Downstream, it silences genes including HOX clusters, CDKN1A (p21), and CDH1 (E-cadherin), thereby affecting cell proliferation, differentiation, and epithelial integrity. Its activity dynamically counteracts histone methyltransferases and intersects with PRC2-mediated silencing, positioning it as a key regulator of chromatin modification and gene expression programs.
In the PaTu 8988t pancreatic cancer model, KDM5D-mediated transcriptional repression may modulate gene programs governing metastasis, tumor growth, and therapeutic response. Disrupting KDM5D in this background enables dissection of epigenetic silencing events that maintain aggressive phenotypes. Comparative analyses between knockout and parental cells can reveal shifts in H3K4 methylation, gene expression profiles, and cellular behaviors such as proliferation, migration, and invasion, providing a versatile platform for studying chromatin modification in pancreatic cancer progression.
Typical research applications include investigating KDM5D??s role in pancreatic cancer progression, analyzing epigenetic mechanisms driving metastasis, and evaluating histone demethylases as therapeutic targets. The polyclonal knockout cells are suitable for a suite of assays: western blotting and RT-qPCR confirm gene disruption and expression changes; ChIP-qPCR for H3K4me3 monitors chromatin state shifts; immunofluorescence visualizes protein localization; cell proliferation and transwell migration/invasion assays quantify functional effects; and RNA-seq provides transcriptome-wide insights into KDM5D-dependent networks. For additional details, please contact Ascent Research.
